USA - NASDAQ:ELAB - US73017P3001 - Common Stock
The current stock price of ELAB is 5.21 USD. In the past month the price decreased by -24.27%. In the past year, price decreased by -94.71%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| KVUE | KENVUE INC | 15.18 | 31.17B | ||
| EL | ESTEE LAUDER COMPANIES-CL A | 51.24 | 31.02B | ||
| ELF | ELF BEAUTY INC | 23.56 | 4.13B | ||
| BRBR | BELLRING BRANDS INC | 11.81 | 3.23B | ||
| COTY | COTY INC-CL A | 17.63 | 2.93B | ||
| IPAR | INTERPARFUMS INC | 16 | 2.69B | ||
| EPC | EDGEWELL PERSONAL CARE CO | 7.01 | 826.99M | ||
| OLPX | OLAPLEX HOLDINGS INC | 12.75 | 680.42M | ||
| NUS | NU SKIN ENTERPRISES INC - A | 6.89 | 470.75M | ||
| NATR | NATURES SUNSHINE PRODS INC | 21.84 | 362.15M | ||
| USNA | USANA HEALTH SCIENCES INC | 9.65 | 345.67M | ||
| HNST | HONEST CO INC/THE | 40.5 | 270.39M |
PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. The company is headquartered in Newport Beach, California and currently employs 2 full-time employees. The company went IPO on 2023-11-21. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
PMGC HOLDINGS INC
120 Newport Center Drive, Ste 250
Newport Beach CALIFORNIA US
Employees: 2
Phone: 18884454886
PMGC Holdings, Inc. is a physician-dispensed skincare company, which engages in the research and development of skincare formulations. The company is headquartered in Newport Beach, California and currently employs 2 full-time employees. The company went IPO on 2023-11-21. The Company’s portfolio consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC. Northstrive Biosciences Inc. is a biopharmaceutical company focusing on the development and acquisition of cutting-edge aesthetic medicines. Its lead asset, EL-22, is leveraging a first-in-class engineered probiotic approach to address obesity’s pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists. PMGC Research Inc. is a research and development subsidiary of the Company, which is focused on advancing the frontiers of scientific discovery. PMGC Capital LLC is a multi-strategy investment vehicle engaging in investing, lending, and seeking diversified investment opportunities across various markets.
The current stock price of ELAB is 5.21 USD. The price decreased by -1.7% in the last trading session.
ELAB does not pay a dividend.
ELAB has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
PMGC HOLDINGS INC (ELAB) has a market capitalization of 2.19M USD. This makes ELAB a Nano Cap stock.
The outstanding short interest for PMGC HOLDINGS INC (ELAB) is 137.73% of its float.
ChartMill assigns a technical rating of 1 / 10 to ELAB. When comparing the yearly performance of all stocks, ELAB is a bad performer in the overall market: 98.25% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to ELAB. While ELAB has a great health rating, there are worries on its profitability.
Over the last trailing twelve months ELAB reported a non-GAAP Earnings per Share(EPS) of -320.19. The EPS increased by 7.83% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -69.45% | ||
| ROE | -93.79% | ||
| Debt/Equity | 0 |